 | • レポートコード：GIR-107A12614 • 出版社/出版日：GlobalInfoResearch / 2021年7月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、81ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療 |
| Single User | ￥515,040 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥772,560 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,030,080 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料では、一次進行性多発性硬化症治療のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。一次進行性多発性硬化症治療の種類別市場規模（ApE、ビオチン、GZ-402668、イブジラスト、イデベノン、ラキニモドナトリウム、その他）、用途別市場規模（病院、クリニック、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・一次進行性多発性硬化症治療の市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：F. Hoffmann-La Roche Ltd.、Genzyme Corporation、Glialogix, Inc.、Kyorin Pharmaceutical Co., Ltd.、MedDay SA、Santhera Pharmaceuticals Holding AG、Teva Pharmaceutical Industries Ltd. ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：ApE、ビオチン、GZ-402668、イブジラスト、イデベノン、ラキニモドナトリウム、その他 ・用途別分析2016年-2026年：病院、クリニック、その他 ・一次進行性多発性硬化症治療の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・一次進行性多発性硬化症治療のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・一次進行性多発性硬化症治療のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・一次進行性多発性硬化症治療の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・一次進行性多発性硬化症治療の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The Primary Progressive Multiple Sclerosis Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest research, the global Primary Progressive Multiple Sclerosis Treatment size is estimated to be USD xx million in 2026 from USD xx million in 2020, with a change XX% between 2020 and 2021. The global Primary Progressive Multiple Sclerosis Treatment market size is expected to grow at a CAGR of xx% for the next five years.
Market segmentation
Primary Progressive Multiple Sclerosis Treatment market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
ApE
Biotin
GZ-402668
Ibudilast
Idebenone
Laquinimod Sodium
Others
Market segment by Application, can be divided into
Hospital
Clinic
Others
Market segment by players, this report covers
F. Hoffmann-La Roche Ltd.
Genzyme Corporation
Glialogix, Inc.
Kyorin Pharmaceutical Co., Ltd.
MedDay SA
Santhera Pharmaceuticals Holding AG
Teva Pharmaceutical Industries Ltd.
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe Primary Progressive Multiple Sclerosis Treatment product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Primary Progressive Multiple Sclerosis Treatment, with revenue, gross margin and global market share of Primary Progressive Multiple Sclerosis Treatment from 2019 to 2021.
Chapter 3, the Primary Progressive Multiple Sclerosis Treatment competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by type and application, with revenue and growth rate by type, application, from 2016 to 2026.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2016 to 2021.and Primary Progressive Multiple Sclerosis Treatment market forecast, by regions, type and application, with revenue, from 2021 to 2026.
Chapter 11 and 12, to describe Primary Progressive Multiple Sclerosis Treatment research findings and conclusion, appendix and data source.
1 Market Overview
1.1 Product Overview and Scope of Primary Progressive Multiple Sclerosis Treatment
1.2 Classification of Primary Progressive Multiple Sclerosis Treatment by Type
1.2.1 Overview: Global Primary Progressive Multiple Sclerosis Treatment Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global Primary Progressive Multiple Sclerosis Treatment Revenue Market Share by Type in 2020
1.2.3 ApE
1.2.4 Biotin
1.2.5 GZ-402668
1.2.6 Ibudilast
1.2.7 Idebenone
1.2.8 Laquinimod Sodium
1.2.9 Others
1.3 Global Primary Progressive Multiple Sclerosis Treatment Market by Application
1.3.1 Overview: Global Primary Progressive Multiple Sclerosis Treatment Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Global Primary Progressive Multiple Sclerosis Treatment Market Size & Forecast
1.5 Global Primary Progressive Multiple Sclerosis Treatment Market Size and Forecast by Region
1.5.1 Global Primary Progressive Multiple Sclerosis Treatment Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global Primary Progressive Multiple Sclerosis Treatment Market Size by Region, (2016-2021)
1.5.3 North America Primary Progressive Multiple Sclerosis Treatment Market Size and Prospect (2016-2026)
1.5.4 Europe Primary Progressive Multiple Sclerosis Treatment Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific Primary Progressive Multiple Sclerosis Treatment Market Size and Prospect (2016-2026)
1.5.6 South America Primary Progressive Multiple Sclerosis Treatment Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa Primary Progressive Multiple Sclerosis Treatment Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 Primary Progressive Multiple Sclerosis Treatment Market Drivers
1.6.2 Primary Progressive Multiple Sclerosis Treatment Market Restraints
1.6.3 Primary Progressive Multiple Sclerosis Treatment Trends Analysis
2 Company Profiles
2.1 F. Hoffmann-La Roche Ltd.
2.1.1 F. Hoffmann-La Roche Ltd. Details
2.1.2 F. Hoffmann-La Roche Ltd. Major Business
2.1.3 F. Hoffmann-La Roche Ltd. Primary Progressive Multiple Sclerosis Treatment Product and Solutions
2.1.4 F. Hoffmann-La Roche Ltd. Primary Progressive Multiple Sclerosis Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 F. Hoffmann-La Roche Ltd. Recent Developments and Future Plans
2.2 Genzyme Corporation
2.2.1 Genzyme Corporation Details
2.2.2 Genzyme Corporation Major Business
2.2.3 Genzyme Corporation Primary Progressive Multiple Sclerosis Treatment Product and Solutions
2.2.4 Genzyme Corporation Primary Progressive Multiple Sclerosis Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 Genzyme Corporation Recent Developments and Future Plans
2.3 Glialogix, Inc.
2.3.1 Glialogix, Inc. Details
2.3.2 Glialogix, Inc. Major Business
2.3.3 Glialogix, Inc. Primary Progressive Multiple Sclerosis Treatment Product and Solutions
2.3.4 Glialogix, Inc. Primary Progressive Multiple Sclerosis Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 Glialogix, Inc. Recent Developments and Future Plans
2.4 Kyorin Pharmaceutical Co., Ltd.
2.4.1 Kyorin Pharmaceutical Co., Ltd. Details
2.4.2 Kyorin Pharmaceutical Co., Ltd. Major Business
2.4.3 Kyorin Pharmaceutical Co., Ltd. Primary Progressive Multiple Sclerosis Treatment Product and Solutions
2.4.4 Kyorin Pharmaceutical Co., Ltd. Primary Progressive Multiple Sclerosis Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 Kyorin Pharmaceutical Co., Ltd. Recent Developments and Future Plans
2.5 MedDay SA
2.5.1 MedDay SA Details
2.5.2 MedDay SA Major Business
2.5.3 MedDay SA Primary Progressive Multiple Sclerosis Treatment Product and Solutions
2.5.4 MedDay SA Primary Progressive Multiple Sclerosis Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.5.5 MedDay SA Recent Developments and Future Plans
2.6 Santhera Pharmaceuticals Holding AG
2.6.1 Santhera Pharmaceuticals Holding AG Details
2.6.2 Santhera Pharmaceuticals Holding AG Major Business
2.6.3 Santhera Pharmaceuticals Holding AG Primary Progressive Multiple Sclerosis Treatment Product and Solutions
2.6.4 Santhera Pharmaceuticals Holding AG Primary Progressive Multiple Sclerosis Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.6.5 Santhera Pharmaceuticals Holding AG Recent Developments and Future Plans
2.7 Teva Pharmaceutical Industries Ltd.
2.7.1 Teva Pharmaceutical Industries Ltd. Details
2.7.2 Teva Pharmaceutical Industries Ltd. Major Business
2.7.3 Teva Pharmaceutical Industries Ltd. Primary Progressive Multiple Sclerosis Treatment Product and Solutions
2.7.4 Teva Pharmaceutical Industries Ltd. Primary Progressive Multiple Sclerosis Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.7.5 Teva Pharmaceutical Industries Ltd. Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Primary Progressive Multiple Sclerosis Treatment Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 3 Primary Progressive Multiple Sclerosis Treatment Players Market Share
3.2.2 Top 10 Primary Progressive Multiple Sclerosis Treatment Players Market Share
3.2.3 Market Competition Trend
3.3 Primary Progressive Multiple Sclerosis Treatment Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Primary Progressive Multiple Sclerosis Treatment Revenue and Market Share by Type (2016-2021)
4.2 Global Primary Progressive Multiple Sclerosis Treatment Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global Primary Progressive Multiple Sclerosis Treatment Revenue Market Share by Application (2016-2021)
5.2 Primary Progressive Multiple Sclerosis Treatment Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America Primary Progressive Multiple Sclerosis Treatment Revenue by Type (2016-2026)
6.2 North America Primary Progressive Multiple Sclerosis Treatment Revenue by Application (2016-2026)
6.3 North America Primary Progressive Multiple Sclerosis Treatment Market Size by Country
6.3.1 North America Primary Progressive Multiple Sclerosis Treatment Revenue by Country (2016-2026)
6.3.2 United States Primary Progressive Multiple Sclerosis Treatment Market Size and Forecast (2016-2026)
6.3.3 Canada Primary Progressive Multiple Sclerosis Treatment Market Size and Forecast (2016-2026)
6.3.4 Mexico Primary Progressive Multiple Sclerosis Treatment Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe Primary Progressive Multiple Sclerosis Treatment Revenue by Type (2016-2026)
7.2 Europe Primary Progressive Multiple Sclerosis Treatment Revenue by Application (2016-2026)
7.3 Europe Primary Progressive Multiple Sclerosis Treatment Market Size by Country
7.3.1 Europe Primary Progressive Multiple Sclerosis Treatment Revenue by Country (2016-2026)
7.3.2 Germany Primary Progressive Multiple Sclerosis Treatment Market Size and Forecast (2016-2026)
7.3.3 France Primary Progressive Multiple Sclerosis Treatment Market Size and Forecast (2016-2026)
7.3.4 United Kingdom Primary Progressive Multiple Sclerosis Treatment Market Size and Forecast (2016-2026)
7.3.5 Russia Primary Progressive Multiple Sclerosis Treatment Market Size and Forecast (2016-2026)
7.3.6 Italy Primary Progressive Multiple Sclerosis Treatment Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Primary Progressive Multiple Sclerosis Treatment Revenue by Type (2016-2026)
8.2 Asia-Pacific Primary Progressive Multiple Sclerosis Treatment Revenue by Application (2016-2026)
8.3 Asia-Pacific Primary Progressive Multiple Sclerosis Treatment Market Size by Region
8.3.1 Asia-Pacific Primary Progressive Multiple Sclerosis Treatment Revenue by Region (2016-2026)
8.3.2 China Primary Progressive Multiple Sclerosis Treatment Market Size and Forecast (2016-2026)
8.3.3 Japan Primary Progressive Multiple Sclerosis Treatment Market Size and Forecast (2016-2026)
8.3.4 South Korea Primary Progressive Multiple Sclerosis Treatment Market Size and Forecast (2016-2026)
8.3.5 India Primary Progressive Multiple Sclerosis Treatment Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia Primary Progressive Multiple Sclerosis Treatment Market Size and Forecast (2016-2026)
8.3.7 Australia Primary Progressive Multiple Sclerosis Treatment Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America Primary Progressive Multiple Sclerosis Treatment Revenue by Type (2016-2026)
9.2 South America Primary Progressive Multiple Sclerosis Treatment Revenue by Application (2016-2026)
9.3 South America Primary Progressive Multiple Sclerosis Treatment Market Size by Country
9.3.1 South America Primary Progressive Multiple Sclerosis Treatment Revenue by Country (2016-2026)
9.3.2 Brazil Primary Progressive Multiple Sclerosis Treatment Market Size and Forecast (2016-2026)
9.3.3 Argentina Primary Progressive Multiple Sclerosis Treatment Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Primary Progressive Multiple Sclerosis Treatment Revenue by Type (2016-2026)
10.2 Middle East & Africa Primary Progressive Multiple Sclerosis Treatment Revenue by Application (2016-2026)
10.3 Middle East & Africa Primary Progressive Multiple Sclerosis Treatment Market Size by Country
10.3.1 Middle East & Africa Primary Progressive Multiple Sclerosis Treatment Revenue by Country (2016-2026)
10.3.2 Turkey Primary Progressive Multiple Sclerosis Treatment Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia Primary Progressive Multiple Sclerosis Treatment Market Size and Forecast (2016-2026)
10.3.4 UAE Primary Progressive Multiple Sclerosis Treatment Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
Table 1. Global Primary Progressive Multiple Sclerosis Treatment Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
Table 2. Global Primary Progressive Multiple Sclerosis Treatment Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
Table 3. Global Market Primary Progressive Multiple Sclerosis Treatment Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
Table 4. Global Primary Progressive Multiple Sclerosis Treatment Revenue (USD Million) by Region (2016-2021)
Table 5. Global Primary Progressive Multiple Sclerosis Treatment Revenue Market Share by Region (2021-2026)
Table 6. F. Hoffmann-La Roche Ltd. Corporate Information, Head Office, and Major Competitors
Table 7. F. Hoffmann-La Roche Ltd. Major Business
Table 8. F. Hoffmann-La Roche Ltd. Primary Progressive Multiple Sclerosis Treatment Product and Solutions
Table 9. F. Hoffmann-La Roche Ltd. Primary Progressive Multiple Sclerosis Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 10. Genzyme Corporation Corporate Information, Head Office, and Major Competitors
Table 11. Genzyme Corporation Major Business
Table 12. Genzyme Corporation Primary Progressive Multiple Sclerosis Treatment Product and Solutions
Table 13. Genzyme Corporation Primary Progressive Multiple Sclerosis Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 14. Glialogix, Inc. Corporate Information, Head Office, and Major Competitors
Table 15. Glialogix, Inc. Major Business
Table 16. Glialogix, Inc. Primary Progressive Multiple Sclerosis Treatment Product and Solutions
Table 17. Glialogix, Inc. Primary Progressive Multiple Sclerosis Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 18. Kyorin Pharmaceutical Co., Ltd. Corporate Information, Head Office, and Major Competitors
Table 19. Kyorin Pharmaceutical Co., Ltd. Major Business
Table 20. Kyorin Pharmaceutical Co., Ltd. Primary Progressive Multiple Sclerosis Treatment Product and Solutions
Table 21. Kyorin Pharmaceutical Co., Ltd. Primary Progressive Multiple Sclerosis Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 22. MedDay SA Corporate Information, Head Office, and Major Competitors
Table 23. MedDay SA Major Business
Table 24. MedDay SA Primary Progressive Multiple Sclerosis Treatment Product and Solutions
Table 25. MedDay SA Primary Progressive Multiple Sclerosis Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 26. Santhera Pharmaceuticals Holding AG Corporate Information, Head Office, and Major Competitors
Table 27. Santhera Pharmaceuticals Holding AG Major Business
Table 28. Santhera Pharmaceuticals Holding AG Primary Progressive Multiple Sclerosis Treatment Product and Solutions
Table 29. Santhera Pharmaceuticals Holding AG Primary Progressive Multiple Sclerosis Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 30. Teva Pharmaceutical Industries Ltd. Corporate Information, Head Office, and Major Competitors
Table 31. Teva Pharmaceutical Industries Ltd. Major Business
Table 32. Teva Pharmaceutical Industries Ltd. Primary Progressive Multiple Sclerosis Treatment Product and Solutions
Table 33. Teva Pharmaceutical Industries Ltd. Primary Progressive Multiple Sclerosis Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 34. Global Primary Progressive Multiple Sclerosis Treatment Revenue (USD Million) by Players (2019-2021)
Table 35. Global Primary Progressive Multiple Sclerosis Treatment Revenue Share by Players (2019-2021)
Table 36. Breakdown of Primary Progressive Multiple Sclerosis Treatment by Company Type (Tier 1, Tier 2 and Tier 3)
Table 37. Primary Progressive Multiple Sclerosis Treatment Players Head Office, Products and Services Provided
Table 38. Primary Progressive Multiple Sclerosis Treatment Mergers & Acquisitions in the Past Five Years
Table 39. Primary Progressive Multiple Sclerosis Treatment New Entrants and Expansion Plans
Table 40. Global Primary Progressive Multiple Sclerosis Treatment Revenue (USD Million) by Type (2016-2021)
Table 41. Global Primary Progressive Multiple Sclerosis Treatment Revenue Share by Type (2016-2021)
Table 42. Global Primary Progressive Multiple Sclerosis Treatment Revenue Forecast by Type (2021-2026)
Table 43. Global Primary Progressive Multiple Sclerosis Treatment Revenue by Application (2016-2021)
Table 44. Global Primary Progressive Multiple Sclerosis Treatment Revenue Forecast by Application (2021-2026)
Table 45. North America Primary Progressive Multiple Sclerosis Treatment Revenue by Type (2016-2021) & (USD Million)
Table 46. North America Primary Progressive Multiple Sclerosis Treatment Revenue by Type (2021-2026) & (USD Million)
Table 47. North America Primary Progressive Multiple Sclerosis Treatment Revenue by Application (2016-2021) & (USD Million)
Table 48. North America Primary Progressive Multiple Sclerosis Treatment Revenue by Application (2021-2026) & (USD Million)
Table 49. North America Primary Progressive Multiple Sclerosis Treatment Revenue by Country (2016-2021) & (USD Million)
Table 50. North America Primary Progressive Multiple Sclerosis Treatment Revenue by Country (2021-2026) & (USD Million)
Table 51. Europe Primary Progressive Multiple Sclerosis Treatment Revenue by Type (2016-2021) & (USD Million)
Table 52. Europe Primary Progressive Multiple Sclerosis Treatment Revenue by Type (2021-2026) & (USD Million)
Table 53. Europe Primary Progressive Multiple Sclerosis Treatment Revenue by Application (2016-2021) & (USD Million)
Table 54. Europe Primary Progressive Multiple Sclerosis Treatment Revenue by Application (2021-2026) & (USD Million)
Table 55. Europe Primary Progressive Multiple Sclerosis Treatment Revenue by Country (2016-2021) & (USD Million)
Table 56. Europe Primary Progressive Multiple Sclerosis Treatment Revenue by Country (2021-2026) & (USD Million)
Table 57. Asia-Pacific Primary Progressive Multiple Sclerosis Treatment Revenue by Type (2016-2021) & (USD Million)
Table 58. Asia-Pacific Primary Progressive Multiple Sclerosis Treatment Revenue by Type (2021-2026) & (USD Million)
Table 59. Asia-Pacific Primary Progressive Multiple Sclerosis Treatment Revenue by Application (2016-2021) & (USD Million)
Table 60. Asia-Pacific Primary Progressive Multiple Sclerosis Treatment Revenue by Application (2021-2026) & (USD Million)
Table 61. Asia-Pacific Primary Progressive Multiple Sclerosis Treatment Revenue by Region (2016-2021) & (USD Million)
Table 62. Asia-Pacific Primary Progressive Multiple Sclerosis Treatment Revenue by Region (2021-2026) & (USD Million)
Table 63. South America Primary Progressive Multiple Sclerosis Treatment Revenue by Type (2016-2021) & (USD Million)
Table 64. South America Primary Progressive Multiple Sclerosis Treatment Revenue by Type (2021-2026) & (USD Million)
Table 65. South America Primary Progressive Multiple Sclerosis Treatment Revenue by Application (2016-2021) & (USD Million)
Table 66. South America Primary Progressive Multiple Sclerosis Treatment Revenue by Application (2021-2026) & (USD Million)
Table 67. South America Primary Progressive Multiple Sclerosis Treatment Revenue by Country (2016-2021) & (USD Million)
Table 68. South America Primary Progressive Multiple Sclerosis Treatment Revenue by Country (2021-2026) & (USD Million)
Table 69. Middle East & Africa Primary Progressive Multiple Sclerosis Treatment Revenue by Type (2016-2021) & (USD Million)
Table 70. Middle East & Africa Primary Progressive Multiple Sclerosis Treatment Revenue by Type (2021-2026) & (USD Million)
Table 71. Middle East & Africa Primary Progressive Multiple Sclerosis Treatment Revenue by Application (2016-2021) & (USD Million)
Table 72. Middle East & Africa Primary Progressive Multiple Sclerosis Treatment Revenue by Application (2021-2026) & (USD Million)
Table 73. Middle East & Africa Primary Progressive Multiple Sclerosis Treatment Revenue by Country (2016-2021) & (USD Million)
Table 74. Middle East & Africa Primary Progressive Multiple Sclerosis Treatment Revenue by Country (2021-2026) & (USD Million)
List of Figures
Figure 1. Primary Progressive Multiple Sclerosis Treatment Picture
Figure 2. Global Primary Progressive Multiple Sclerosis Treatment Revenue Market Share by Type in 2020
Figure 3. ApE
Figure 4. Biotin
Figure 5. GZ-402668
Figure 6. Ibudilast
Figure 7. Idebenone
Figure 8. Laquinimod Sodium
Figure 9. Others
Figure 10. Primary Progressive Multiple Sclerosis Treatment Revenue Market Share by Application in 2020
Figure 11. Hospital Picture
Figure 12. Clinic Picture
Figure 13. Others Picture
Figure 14. Global Primary Progressive Multiple Sclerosis Treatment Revenue, (USD Million): 2020 VS 2021 VS 2026
Figure 15. Global Primary Progressive Multiple Sclerosis Treatment Revenue and Forecast (2016-2026) & (USD Million)
Figure 16. Global Primary Progressive Multiple Sclerosis Treatment Revenue Market Share by Region (2016-2026)
Figure 17. Global Primary Progressive Multiple Sclerosis Treatment Revenue Market Share by Region in 2020
Figure 18. North America Primary Progressive Multiple Sclerosis Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 19. Europe Primary Progressive Multiple Sclerosis Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 20. Asia-Pacific Primary Progressive Multiple Sclerosis Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 21. South America Primary Progressive Multiple Sclerosis Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 22. Middle East and Africa Primary Progressive Multiple Sclerosis Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 23. Primary Progressive Multiple Sclerosis Treatment Market Drivers
Figure 24. Primary Progressive Multiple Sclerosis Treatment Market Restraints
Figure 25. Primary Progressive Multiple Sclerosis Treatment Market Trends
Figure 26. F. Hoffmann-La Roche Ltd. Recent Developments and Future Plans
Figure 27. Genzyme Corporation Recent Developments and Future Plans
Figure 28. Glialogix, Inc. Recent Developments and Future Plans
Figure 29. Kyorin Pharmaceutical Co., Ltd. Recent Developments and Future Plans
Figure 30. MedDay SA Recent Developments and Future Plans
Figure 31. Santhera Pharmaceuticals Holding AG Recent Developments and Future Plans
Figure 32. Teva Pharmaceutical Industries Ltd. Recent Developments and Future Plans
Figure 33. Global Primary Progressive Multiple Sclerosis Treatment Revenue Share by Players in 2020
Figure 34. Primary Progressive Multiple Sclerosis Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
Figure 35. Global Top 3 Players Primary Progressive Multiple Sclerosis Treatment Revenue Market Share in 2020
Figure 36. Global Top 10 Players Primary Progressive Multiple Sclerosis Treatment Revenue Market Share in 2020
Figure 37. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
Figure 38. Global Primary Progressive Multiple Sclerosis Treatment Revenue Share by Type in 2020
Figure 39. Global Primary Progressive Multiple Sclerosis Treatment Market Share Forecast by Type (2021-2026)
Figure 40. Global Primary Progressive Multiple Sclerosis Treatment Revenue Share by Application in 2020
Figure 41. Global Primary Progressive Multiple Sclerosis Treatment Market Share Forecast by Application (2021-2026)
Figure 42. North America Primary Progressive Multiple Sclerosis Treatment Sales Market Share by Type (2016-2026)
Figure 43. North America Primary Progressive Multiple Sclerosis Treatment Sales Market Share by Application (2016-2026)
Figure 44. North America Primary Progressive Multiple Sclerosis Treatment Revenue Market Share by Country (2016-2026)
Figure 45. United States Primary Progressive Multiple Sclerosis Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 46. Canada Primary Progressive Multiple Sclerosis Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 47. Mexico Primary Progressive Multiple Sclerosis Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 48. Europe Primary Progressive Multiple Sclerosis Treatment Sales Market Share by Type (2016-2026)
Figure 49. Europe Primary Progressive Multiple Sclerosis Treatment Sales Market Share by Application (2016-2026)
Figure 50. Europe Primary Progressive Multiple Sclerosis Treatment Revenue Market Share by Country (2016-2026)
Figure 51. Germany Primary Progressive Multiple Sclerosis Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 52. France Primary Progressive Multiple Sclerosis Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 53. United Kingdom Primary Progressive Multiple Sclerosis Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 54. Russia Primary Progressive Multiple Sclerosis Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 55. Italy Primary Progressive Multiple Sclerosis Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 56. Asia-Pacific Primary Progressive Multiple Sclerosis Treatment Sales Market Share by Type (2016-2026)
Figure 57. Asia-Pacific Primary Progressive Multiple Sclerosis Treatment Sales Market Share by Application (2016-2026)
Figure 58. Asia-Pacific Primary Progressive Multiple Sclerosis Treatment Revenue Market Share by Region (2016-2026)
Figure 59. China Primary Progressive Multiple Sclerosis Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 60. Japan Primary Progressive Multiple Sclerosis Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 61. South Korea Primary Progressive Multiple Sclerosis Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 62. India Primary Progressive Multiple Sclerosis Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 63. Southeast Asia Primary Progressive Multiple Sclerosis Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 64. Australia Primary Progressive Multiple Sclerosis Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 65. South America Primary Progressive Multiple Sclerosis Treatment Sales Market Share by Type (2016-2026)
Figure 66. South America Primary Progressive Multiple Sclerosis Treatment Sales Market Share by Application (2016-2026)
Figure 67. South America Primary Progressive Multiple Sclerosis Treatment Revenue Market Share by Country (2016-2026)
Figure 68. Brazil Primary Progressive Multiple Sclerosis Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 69. Argentina Primary Progressive Multiple Sclerosis Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 70. Middle East and Africa Primary Progressive Multiple Sclerosis Treatment Sales Market Share by Type (2016-2026)
Figure 71. Middle East and Africa Primary Progressive Multiple Sclerosis Treatment Sales Market Share by Application (2016-2026)
Figure 72. Middle East and Africa Primary Progressive Multiple Sclerosis Treatment Revenue Market Share by Country (2016-2026)
Figure 73. Turkey Primary Progressive Multiple Sclerosis Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 74. Saudi Arabia Primary Progressive Multiple Sclerosis Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 75. UAE Primary Progressive Multiple Sclerosis Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 76. Methodology
Figure 77. Research Process and Data Source
世界の進行性再発性多発性硬化症治療市場 2021：企業別、地域別、種類・用途別 The Progressive Relapsing Multiple Sclerosis Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain …- 世界の多発性硬化症治療薬市場 2021：企業別、地域別、種類・用途別 The Multiple Sclerosis Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regula…
- 世界の原発性胆汁性胆管炎治療市場 2021：企業別、地域別、種類・用途別 The Primary Biliary Cholangitis Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization,…
- 世界の全身性硬化症治療市場 2021：企業別、地域別、種類・用途別 The Systemic Sclerosis Treatments market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade r…
- 世界の一次上下水処理装置市場 2021：企業別、地域別、種類・用途別 The Primary Water And Wastewater Treatment Equipment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain op…